Baseline patient characteristics (n = 282)
| . | N or median . | % or range . |
|---|---|---|
| Age (y) | 71 | 20-89 |
| Sex | ||
| Male | 173 | 61 |
| Female | 109 | 39 |
| Secondary MDS | 74 | 26 |
| WHO diagnosis | ||
| RA/RARS/RCMD | 12 | 4 |
| RAEB1 | 56 | 20 |
| RAEB2 | 151 | 54 |
| AML (RAEB-t) | 63 | 22 |
| Cytogenetic risk (IPSS) | ||
| Favorable | 88 | 31 |
| Intermediate | 46 | 17 |
| Unfavorable | 133 | 47 |
| Failure | 15 | 5 |
| IPSS risk | ||
| Intermediate-2 | 153 | 54 |
| High | 122 | 43 |
| Na (int-2 or high) | 7 | 2 |
| ECOG PS | ||
| 0-1 | 217 | 77 |
| ≥ 2 | 56 | 20 |
| Na | 9 | 3 |
| Hb < 11 g/dL and/or RBC transfusion dependence | 256 | 91 |
| RBC transfusion dependence | ||
| ≥ 4 RBC units/8 w | 128 | 45 |
| 1-3 RBC units/8 w | 60 | 21 |
| No RBC transfusion dependence | 91 | 32 |
| Na | 3 | 1 |
| ANC < 1.0 G/L | 154 | 55 |
| PLT < 100 G/L | 209 | 74 |
| PB blasts | ||
| Present | 127 | 45 |
| Absent | 147 | 52 |
| Na | 8 | 3 |
| Interval from diagnosis (mo) | 5 | 0-143 |
| Prior treatment with LD AraC | ||
| Yes | 29 | 10 |
| No | 243 | 86 |
| Na | 10 | 4 |
| Prior treatment with ESA | ||
| Yes | 91 | 32 |
| No | 190 | 67 |
| Na | 1 | 1 |
| AZA schedule | ||
| Standard (75 mg/m2/d during 7 d every 28 d) | 202 | 72 |
| < 75 mg/m2/d for 7 d/cycle | 16 | 6 |
| 75 mg/m2/d for 5 d/cycle | 55 | 19 |
| < 75 mg/m2/d for 5 d/cycle | 9 | 3 |
| Number of AZA cycles (median, range) | 6 | 1-52 |
| Median follow-up (mo, range) | 26 | 6-52 |
| . | N or median . | % or range . |
|---|---|---|
| Age (y) | 71 | 20-89 |
| Sex | ||
| Male | 173 | 61 |
| Female | 109 | 39 |
| Secondary MDS | 74 | 26 |
| WHO diagnosis | ||
| RA/RARS/RCMD | 12 | 4 |
| RAEB1 | 56 | 20 |
| RAEB2 | 151 | 54 |
| AML (RAEB-t) | 63 | 22 |
| Cytogenetic risk (IPSS) | ||
| Favorable | 88 | 31 |
| Intermediate | 46 | 17 |
| Unfavorable | 133 | 47 |
| Failure | 15 | 5 |
| IPSS risk | ||
| Intermediate-2 | 153 | 54 |
| High | 122 | 43 |
| Na (int-2 or high) | 7 | 2 |
| ECOG PS | ||
| 0-1 | 217 | 77 |
| ≥ 2 | 56 | 20 |
| Na | 9 | 3 |
| Hb < 11 g/dL and/or RBC transfusion dependence | 256 | 91 |
| RBC transfusion dependence | ||
| ≥ 4 RBC units/8 w | 128 | 45 |
| 1-3 RBC units/8 w | 60 | 21 |
| No RBC transfusion dependence | 91 | 32 |
| Na | 3 | 1 |
| ANC < 1.0 G/L | 154 | 55 |
| PLT < 100 G/L | 209 | 74 |
| PB blasts | ||
| Present | 127 | 45 |
| Absent | 147 | 52 |
| Na | 8 | 3 |
| Interval from diagnosis (mo) | 5 | 0-143 |
| Prior treatment with LD AraC | ||
| Yes | 29 | 10 |
| No | 243 | 86 |
| Na | 10 | 4 |
| Prior treatment with ESA | ||
| Yes | 91 | 32 |
| No | 190 | 67 |
| Na | 1 | 1 |
| AZA schedule | ||
| Standard (75 mg/m2/d during 7 d every 28 d) | 202 | 72 |
| < 75 mg/m2/d for 7 d/cycle | 16 | 6 |
| 75 mg/m2/d for 5 d/cycle | 55 | 19 |
| < 75 mg/m2/d for 5 d/cycle | 9 | 3 |
| Number of AZA cycles (median, range) | 6 | 1-52 |
| Median follow-up (mo, range) | 26 | 6-52 |